Jones Financial Companies
MTNB icon

Jones Financial Companies’s Matinas BioPharma MTNB Stock Holding History

Jones Financial Companies’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39 Hold
60
– – ﹤0.01% 4920
2026
Q1 		$34 Hold
60
– – ﹤0.01% 4681
2025
Q4 		$35 Hold
60
– – ﹤0.01% 4352
2025
Q3 		$114 Hold
60
– – ﹤0.01% 4157
2025
Q2 		$55 Buy
+60
New +$44 ﹤0.01% 3971

Other funds holding MTNB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Jones Financial Companies's MTNB Position: Q2 2026 in Review

Jones Financial Companies held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 60 shares worth $39. The position accounts for ﹤0.01% of the portfolio, ranked #4920.

Jones Financial Companies first reported a position in MTNB in Q2 2025 and has held it in 5 quarters since. The position peaked at $114 in Q3 2025. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • Jones Financial Companies held 60 shares of Matinas BioPharma worth $39 as of Q2 2026.
  • Jones Financial Companies left its Matinas BioPharma share count unchanged in Q2 2026.
  • Matinas BioPharma made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4920 holding.
  • Jones Financial Companies first reported a position in Matinas BioPharma in Q2 2025 and has held it in 5 quarters since.
  • Jones Financial Companies's Matinas BioPharma position peaked at $114 in Q3 2025.
  • 25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.